Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103158 | 0.79 | MAOB (0.63) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL30036439 | 0.79 | MAOB (0.63) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL15157317 | 0.77 | APP (0.54) | MAOBNPC1RAB9AMAPTADRA2A | |
| SCHEMBL3766008 | 0.75 | ADRA2A (0.50) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL2150499 | 0.74 | MAOB (0.59) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL4810005 | 0.74 | MAOB (0.46) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL1567277 | 0.73 | MAOB (0.62) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL7909606 | 0.73 | NPC1 (0.45) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL4231610 | 0.73 | ADRA2A (0.47) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL2149640 | 0.73 | MAOB (0.57) | MAOBMAOAALOX5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109564972-B | Organic light emitting element | 株式会社LG化学 | 2023-02-03 | — | — | CN | claimed |
| CN-114516804-A | Diamine derivative and organic electroluminescent device using same | 江苏三月科技股份有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-109311844-B | Triazine compound, method for producing same, and organic electroluminescent element containing same as constituent component | 东曹株式会社 | 2021-07-20 | — | — | CN | claimed |
| EP-3579292-B1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEMICAL LTD (KR) | 2020-08-05 | — | — | EP | claimed |
| EP-3579292-A1 | ORGANIC LIGHT EMITTING DEVICE | LG Chem, Ltd. (KR) | 2019-12-11 | — | — | EP | claimed |
| CN-109564972-A | Organic light emitting element | 株式会社LG化学 | 2019-04-02 | — | — | CN | claimed |
| CN-106573912-A | Triazine compound, method for producing same, and application for same | 东曹株式会社 | 2017-04-19 | — | — | CN | claimed |
| US-9447065-B2 | Pharmaceutical composition | RAQUALIA PHARMA INC. (JP) | 2016-09-20 | — | — | US | claimed |
| EP-2979695-A1 | THERAPEUTIC AGENT FOR EYE DISORDER | AskAt Inc. (JP) | 2016-02-03 | — | — | EP | claimed |
| US-20160008317-A1 | THERAPEUTIC AGENT FOR OCULAR DISEASE | ASKAT INC. (JP) | 2016-01-14 | — | — | US | claimed |
| EP-1123285-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2001-08-16 | — | — | EP | claimed |
| US-6271253-B1 | CYCLOOXYGENASE INHIBITORS | G.D. SEARLE & CO. | 2001-08-07 | — | — | US | claimed |
| WO-2001049675-A1 | DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS | PHARMACIA CORPORATION (US) | 2001-07-12 | — | — | WO | claimed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | claimed |
| US-6077850-A | USEFUL FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS INFLAMMATION AND INFLAMMATION-RELATED DISORDERS | G.D. SEARLE & CO. (US) | 2000-06-20 | — | — | US | claimed |
| WO-2000023433-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-04-27 | — | — | WO | claimed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | claimed |
| EP-0977748-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047890-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | claimed |
| US-4122256-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008317-A1 | THERAPEUTIC AGENT FOR OCULAR DISEASE | ALDH1A2, PDE6C, PDE6A | MAOB 2725/4885MAOA 2417/4885ALOX5 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.